119 results
Page 2 of 6
8-K
EX-99.1
56u5xcefxc t9
26 Jul 23
Better Therapeutics Announces $6.7 Million in New Financing at an Average Price of $0.77 per Share
5:11pm
8-K
EX-10.1
6jvg9cgu
26 Jul 23
Better Therapeutics Announces $6.7 Million in New Financing at an Average Price of $0.77 per Share
5:11pm
8-K
EX-10.2
npx sji4y1
26 Jul 23
Better Therapeutics Announces $6.7 Million in New Financing at an Average Price of $0.77 per Share
5:11pm
8-K
EX-99.1
tb5dhrig8m1 wopmx2
12 Jul 23
Better Therapeutics Receives FDA Authorization for AspyreRxTM to Treat Adults with Type 2 Diabetes
12:00am
8-K
EX-10.1
dnenja r12ocd7
11 May 23
Entry into a Material Definitive Agreement
5:23pm
8-K
EX-99.1
nhmv5hafz6ag48yx a3
11 May 23
Better Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
7:33am
8-K
EX-10.1
kufn1v pl4elxztr
7 Apr 23
Better Therapeutics Announces $6.5MM Private Placement
4:52pm
8-K
EX-99.1
c94a0y2
7 Apr 23
Better Therapeutics Announces $6.5MM Private Placement
4:52pm
8-K
EX-99.1
vdxkvyxapwi0vd38
30 Mar 23
Better Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
7:40am
8-K
EX-99.1
e324k24
9 Dec 22
Better Therapeutics Completes Exploratory Trial for Fatty Liver Disease and Announces Positive Topline Results
6:56pm
8-K
EX-99.2
8md23
9 Dec 22
Better Therapeutics Completes Exploratory Trial for Fatty Liver Disease and Announces Positive Topline Results
6:56pm
424B3
kli5dt7jzn2b992hxcv
15 Nov 22
Prospectus supplement
9:56pm
8-K
EX-99.1
x4lit8v atnwm
14 Nov 22
Better Therapeutics Reports Third Quarter 2022 Financial Results and Provides
4:10pm
8-K
EX-99.1
f8hjb fwa
2 Nov 22
Better Therapeutics Appoints Diane Gomez-Thinnes as Chief Commercial Officer
5:07pm
8-K
EX-99.1
2y9vl3
22 Sep 22
Regulation FD Disclosure
7:41am
8-K
EX-99.1
uxn1cd7
13 Sep 22
Regulation FD Disclosure
5:32pm